\
&
Contact us
\
&
Contact us
This was 10 months ago
LocationBrussels and online
The aim of the GENDERACTIONplus conference Towards new Horizons: Inclusive Gender Equality in FP10 and Beyond is to review the progress made in advancing inclusive gender equality in research and innovation in the EU, assess advances in policy coordination accomplished through GENDERACTIONplus Communities of Practice, and engage in a 'whole system’ dialogue with policy makers, research funders, ERA stakeholder organisations, ERA gender equality officers, and scholars, to discuss the challenges and opportunities ahead.
More information on the conference including the programme and registration form is available in the announcement on the GENDERACTIONplus project webpage. The onsite registrations close on 31 January 2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Digital, Industry & Space Digital Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
